Evidence map›Paper›PMID 38836758›Full record

ArticleCancer research communications2024

Association of ESR1 Germline Variants with TP53 Somatic Variants in Breast Tumors in a Genome-wide Study.

Nijole P Tjader, Abigail J Beer, Johnny Ramroop, Mei-Chee Tai, Jie Ping, Tanish Gandhi, Cara Dauch, Susan L Neuhausen, Elad Ziv, Nereida Sotelo and 23 more

Abstract read
In one paragraph

Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors.

Nijole P TjaderDepartment of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, Ohio.ORCID 0000-0001-7438-9942
Abigail J BeerDepartment of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, Ohio.ORCID 0000-0003-3927-9451
Johnny RamroopThe City College of New York, City University of New York, New York, New York.ORCID 0009-0008-6075-0643
Mei-Chee TaiCancer Research Malaysia, Subang Jaya, Selangor, Malaysia.ORCID 0000-0002-6191-9593
Jie PingDivision of Epidemiology, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.ORCID 0000-0001-9907-5819
Tanish GandhiBiomedical Sciences, The Ohio State University College of Medicine, Columbus, Ohio.ORCID 0009-0007-6479-2173
Cara DauchDepartment of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, Ohio.ORCID 0009-0003-4783-9209
Susan L NeuhausenDepartment of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California.ORCID 0000-0001-5053-0390
Elad ZivHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-2324-2884
Nereida SoteloDepartment of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, Ohio.ORCID 0009-0007-7174-4575
Shreya GhanekarDepartment of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, Ohio.ORCID 0009-0001-7653-6990
Owen MeadowsBiomedical Sciences, The Ohio State University College of Medicine, Columbus, Ohio.ORCID 0009-0005-6833-2823
Monica ParedesBiomedical Sciences, The Ohio State University College of Medicine, Columbus, Ohio.ORCID 0009-0000-9343-6767
Jessica L GillespieThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0009-0002-1592-193X
Amber M AeiltsDepartment of Internal Medicine, Division of Human Genetics, The Ohio State University, Columbus, Ohio.ORCID 0000-0001-8907-7853
Heather HampelDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California.ORCID 0000-0001-7558-9794
Wei ZhengDivision of Epidemiology, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.ORCID 0000-0003-1226-070X
Guochong JiaDivision of Epidemiology, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.ORCID 0000-0002-8455-1832
Qiang HuDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0002-4090-5539
Lei WeiDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0002-1881-8666
Song LiuDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0001-6351-2941
Christine B AmbrosoneDepartment of Cancer Control and Prevention, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0003-1717-9943
Julie R PalmerSlone Epidemiology Center at Boston University, Boston, Massachusetts.ORCID 0000-0002-6534-335X
John D CarptenCity of Hope Comprehensive Cancer Center, Duarte, California.ORCID 0000-0002-6862-2821
Song YaoDepartment of Cancer Control and Prevention, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0001-9442-1313
Patrick StevensBioinformatics Shared Resource, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0002-5288-195X
Weang-Kee HoCancer Research Malaysia, Subang Jaya, Selangor, Malaysia.ORCID 0000-0002-8269-7344
Jia Wern PanCancer Research Malaysia, Subang Jaya, Selangor, Malaysia.ORCID 0000-0003-0875-9831
Paolo FaddaGenomics Shared Resource, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0001-9444-1461
Dezheng HuoDepartment of Public Health Sciences, University of Chicago, Chicago, Illinois.ORCID 0000-0002-4041-1678
Soo-Hwang TeoCancer Research Malaysia, Subang Jaya, Selangor, Malaysia.ORCID 0000-0002-0444-590X
Joseph Paul McElroyDepartment of Biomedical Informatics, The Ohio State University Center for Biostatistics, Columbus, Ohio.ORCID 0000-0003-0366-1210
Amanda E TolandDepartment of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, Ohio.ORCID 0000-0002-0271-1792

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI John Charles Williams · 1985 to 2026
$86.3M
A Follow-up Study for Causes of Cancer in Black WomenU01CA164974 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Kimberly A. Bertrand, Yvette C Cozier · 2017 to 2026
$24.0M
Breast Cancer genetic study in African-ancestry populationsR01CA202981 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Wei Zheng · 2016 to 2026
$14.1M
A Follow-up Study for Causes of Cancer in Black WomenUM1CA164974 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ROSENBERG, LYNN · 2012 to 2017
$13.7M
Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCIU24CA232979 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI HUTSON, ALAN DAVID, LIU, SONG · 2018 to 2024
$8.9M
YAP1 and RB1 cooperate to regulate lung cancer lineage plasticity and therapeutic resistanceU24CA274159 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI DAVID W. GOODRICH, Alan David Hutson · 2022 to 2026
$8.5M
Somatic Mutations and Their Etiological Determinants for Breast Cancer in African American WomenR01CA228156 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CARPTEN, JOHN D., PALMER, JULIE R · 2019 to 2023
$6.5M
Germline and Tumor Genomic Analyses of Breast Cancer in LatinasR01CA184585 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI NEUHAUSEN, SUSAN L., ZIV, ELAD · 2014 to 2018
$4.2M
Polygenic Risk Prediction of Breast Cancer for Women of African DescentR01CA228198 · NCI · UNIVERSITY OF CHICAGO · PI Dezheng Huo · 2018 to 2026
$3.9M
Advancing skin cancer prevention by tackling UV-induced clonogenic mutationsR01CA255242 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI PARAGH, GYORGY, WEI, LEI · 2021 to 2025
$3.2M
California Initiative to Advance Precision Medicine OPR18111Estée Lauder CompaniesHHS | NIH | National Cancer Institute (NCI) K24CA169004HHS | NIH | National Cancer Institute (NCI) P30CA033572HHS | NIH | National Cancer Institute (NCI) P30CA068485HHS | NIH | National Cancer Institute (NCI) R01CA164974HHS | NIH | National Cancer Institute (NCI) R01CA184585HHS | NIH | National Cancer Institute (NCI) R01CA202981HHS | NIH | National Cancer Institute (NCI) R01 CA215151-01HHS | NIH | National Cancer Institute (NCI) R01CA228156HHS | NIH | National Cancer Institute (NCI) R01CA228198HHS | NIH | National Cancer Institute (NCI) R01CA255242HHS | NIH | National Cancer Institute (NCI) U24CA232979HHS | NIH | National Cancer Institute (NCI) U24CA274159HHS | NIH | National Institute on Minority Health and Health Disparities (NIMHD) R01MD013452Morris and Horowitz Families ProfessorshipNCI NIH HHS K24 CA169004NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA033572NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA184585NCI NIH HHS R01 CA202981NCI NIH HHS R01 CA215151NCI NIH HHS R01 CA228156NCI NIH HHS R01 CA228198NCI NIH HHS R01 CA255242NCI NIH HHS U01 CA164974NCI NIH HHS U24 CA232979NCI NIH HHS U24 CA274159Newton-Ungku Omar Fund MR/P012930/1NIMHD NIH HHS R01 MD013452OSU CCC CreatesPelotoniaScientex FoundationWellcome TrustWellcome Trust (WT) v203477/Z/16/ZYayasan PETRONASYayasan Sime Darby (YSD)
6 · The paper itself

Abstract

In breast tumors, somatic mutation frequencies in TP53 and PIK3CA vary by tumor subtype and ancestry. Emerging data suggest tumor mutation status is associated with germline variants and genetic ancestry. We aimed to identify germline variants that are associated with somatic TP53 or PIK3CA mutation status in breast tumors. A genome-wide association study was conducted in 2,850 women of European ancestry with breast cancer using TP53 and PIK3CA mutation status (positive or negative) as well as specific functional categories [e.g., TP53 gain-of-function (GOF) and loss-of-function, PIK3CA activating] as phenotypes. Germline variants showing evidence of association were selected for validation analyses and tested in multiple independent datasets. Discovery association analyses found five variants associated with TP53 mutation status with P values <1 × 10-6 and 33 variants with P values <1 × 10-5. Forty-four variants were associated with PIK3CA mutation status with P values <1 × 10-5. In validation analyses, only variants at the ESR1 locus were associated with TP53 mutation status after multiple comparisons corrections. Combined analyses in European and Malaysian populations found ESR1 locus variants rs9383938 and rs9479090 associated with the presence of TP53 mutations overall (P values 2 × 10-11 and 4.6 × 10-10, respectively). rs9383938 also showed association with TP53 GOF mutations (P value 6.1 × 10-7). rs9479090 showed suggestive evidence (P value 0.02) for association with TP53 mutation status in African ancestry populations. No other variants were significantly associated with TP53 or PIK3CA mutation status. Larger studies are needed to confirm these findings and determine if additional variants contribute to ancestry-specific differences in mutation frequency. SIGNIFICANCE: Emerging data show ancestry-specific differences in TP53 and PIK3CA mutation frequency in breast tumors suggesting that germline variants may influence somatic mutational processes. This study identified variants near ESR1 associated with TP53 mutation status and identified additional loci with suggestive association which may provide biological insight into observed differences.

Indexed as

Breast NeoplasmsClass I Phosphatidylinositol 3-KinasesEstrogen Receptor alphaGenome-Wide Association StudyGerm-Line MutationTumor Suppressor Protein p53AdultFemaleGenetic Predisposition to DiseaseHumansMiddle AgedPolymorphism, Single NucleotideSoutheast Asian PeopleWhite PeopleClass I Phosphatidylinositol 3-KinasesESR1 protein, humanEstrogen Receptor alphaPIK3CA protein, humanTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID38836758
PMCPMC11210444

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.